首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1863949

抗体药物复合体市场按产品类型、连接子类型、应用、分销管道和地区划分

Antibody Drug Conjugates Market, By Product Type, By Linker Type, By Application, By Distribution Channel, By Geography

出版日期: 2025年10月04日 | 出版商:

Coherent Market Insights | 英文 210 Pages | 商品交期: 2-3个工作天内

价格

简介目录

抗体药物复合体(ADC) 市场预计在 2025 年达到 70.1 亿美元，预计到 2032 年将达到 177.6 亿美元，2025 年至 2032 年的复合年增长率为 14.2%。

报告范围		报告详情
基准年：	2024	2025年市场规模：	70.1亿美元
性能数据：	2020年至2024年	预测期：	2025年至2032年
预测期（2025-2032年）复合年增长率：	14.20%	2032 年价值预测：	177.6亿美元

抗体药物复合体（ADC）是标靶治疗药物，可将化疗药物递送至癌细胞。 ADC 的作用抗体药物复合体抗体药物复合体静脉注射，它会与癌细胞表面的标靶抗原结合，导致内吞作用。内化的囊泡与其他囊泡融合，进入内体-溶小体路径。在溶小体中，蛋白酶降解单株抗体，释放出游离药物。药物随后穿过溶酶体膜，进入细胞质和/或细胞核，并与目标分子结合，导致细胞死亡。

市场动态

市场相关人员正积极进行研发活动，这有望在预测期内推动全球抗体药物复合体）市场的成长。例如，2021年4月5日，专注于肿瘤治疗且商业性成功的生物技术公司Exelix宣布，美国食品药物管理局（FDA）已受理其临床实验新药（IND）申请，以评估XB002在进行性固态肿瘤患者中的安全性、耐受性、药物动力学和初步抗肿瘤活性。 XB002是一种新一代组织因子靶向抗体药物复合体（ADC），与传统的组织因子靶向ADC相比，可能具有更宽的治疗指数和更优的安全性。

市场相关人员正专注于策略合作与协议，预计这将推动全球抗体药物复合体市场的成长。例如，2021年6月17日，世界领先的研髮型製药公司Eisai和全球生物製药公司百时美施贵宝公司宣布达成一项全球独家战略合作协议，共同开发和商业化抗体药物复合体（ADC）MORAb-202。

市场参与者和政府机构正采取收购和合作等策略来扩大其全球影响力，预计将推动全球抗体药物复合体（ADC）市场的成长。例如，2020年9月13日，以研发为基础的生物製药公司吉利德科学公司（Gilead Sciences, Inc.）和新一代抗体药物偶联物（ADC）技术领域的领导者Immunomedics公司宣布达成最终协议，吉利德将以每股88美元的现金收购Immunomedics。根据协议条款，吉利德将收购Trodelvy（sacituzumab govitecan-hziy），这是First-in-Class抗体药物复合体（ADC），于美国年4月获得美国食品食品药物管理局（ FDA）加速核准，用于核准转移性三阴性乳癌（mTNBC）成人患者。

本次调查的主要特点

本报告对全球抗体药物复合体(ADC) 市场进行了详细分析，并以 2024 年为基准年，给出了 2025-2032 年预测期的市场规模。
该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、区域前景以及推动市场发展的主要企业的竞争策略的重要见解。
该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、区域前景以及主要企业采取的竞争策略的重要见解。
本报告根据以下参数介绍了全球抗体药物复合体市场主要企业的概况：公司概况、财务表现、产品系列、地理扩张、分销策略、关键发展和策略以及未来计划。
本报告的研究结果将帮助负责人和经营团队就即将推出的产品、技术升级、市场扩张和行销策略做出明智的决策。
本报告的目标受众是全球抗体药物复合体(ADC) 市场的各个相关人员，包括投资者、供应商、製造商、经销商、新参与企业和金融分析师。
相关人员可以透过各种用于分析全球抗体药物复合体市场的策略矩阵轻鬆做出决策。

公司简介
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics（Suzhou）Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd

第十章各节

参考
调查方法

简介目录

Product Code: CMI181

Antibody Drug Conjugates Market is estimated to be valued at USD 7.01 Bn in 2025 and is expected to reach USD 17.76 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.2% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 7.01 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	14.20%	2032 Value Projection:	USD 17.76 Bn

Antibody Drug Conjugates (ADCs) are targeted medicines that deliver chemotherapy drugs to cancer cells. The mechanism of action (MOA) of antibody-drug conjugates is fairly straightforward. When a portion of the antibody-drug conjugate is administered intravenously and binds to a target antigen on the cell surface of the tumor cell, the complex is internalized. Internalized vesicles fuse with other vesicles and enter the endosome-lysosome pathway after internalization. In the lysosome, proteases digest the monoclonal antibody to release free payloads, which then cross the lysosome membrane to enter the cytoplasm and/or nucleus, where they bind to the target molecule, causing cell death.

Market Dynamics

Market players are involved in research and development activities, this could contribute to the growth of the global antibody drug conjugates market over the forecast period. For instance, on April 05, 2021, Exelixis, Inc., a commercially successful oncology-focused biotechnology company, announced that the U.S. Food and Drugs Administration (FDA) accepted their Investigational New Drug Application (IND) to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of XB002 in patients with advanced solid tumors. XB002, as a next-generation tissue factor-targeting antibody-drug conjugate (ADC), has the potential for a higher therapeutic index and a better safety profile than earlier-generation tissue factor-targeting ADCs.

Market players are focused on strategic collaborations and agreements, which is expected to propel the growth of the global antibody drug conjugates market. For instance, on June 17, 2021, Eisai Co., Ltd., a leading global R&D-based pharmaceutical company, and Bristol-Myers Squibb Company, a global biopharmaceutical company, announced an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).

Market players and government authorities are involved in expanding their global presence by adopting strategies such as acquisitions and collaborations, which is expected to drive the growth of the global antibody drug conjugates market. For instance, on September 13, 2020, Gilead Sciences, Inc., a research-based biopharmaceutical company, and Immunomedics, a leader in next-generation antibody-drug conjugate (ADC) technology, announced a definitive agreement under which Gilead will acquire Immunomedics for US$ 88.00 per share in cash. Under the terms of agreement, Gilead will be provided with Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April 2020, for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC).

Key features of the study

This report provides an in-depth analysis of global antibody drug conjugates market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global antibody drug conjugates market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd., Astellas Pharma, ADC Therapeutics, Pfizer, Inc., Seagen, Inc., Daiichi Sankyo Company Ltd., and Oxford Biotherapeutics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global antibody drug conjugates market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global antibody drug conjugates market

Market Segmentation

Product Type Insights (Revenue, US$ Bn, 2025 - 2032)
- Adcetris
- Kadcyla
- Enhertu
- Trodelvy
- Padcev
- Others
Linker Type Insights (Revenue, US$ Bn, 2025 - 2032)
- Non-cleavable Linker
- Cleavable Linker
Application Insights (Revenue, US$ Bn, 2025 - 2032)
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Skin Cancer
- Brain Tumor
- Others
Distribution Channel Insights (Revenue, US$ Bn, 2025 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
Regional Insights (Revenue, US$ Bn, 2025 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- Rest of Middle East & Africa
Key Players Insights
- AstraZeneca PLC
- Daiichi Sankyo Company Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics (Suzhou) Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Linker Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Antibody Drug Conjugates Market, By Product Type, 2020 - 2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adcetris
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
Kadcyla
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
Besponsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
Lumoxiti
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
Mylotarg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
Others (Polivy, Lumoxiti, Zynlonta, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends

5. Global Antibody Drug Conjugates Market, By Linker Type, 2020 - 2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Non-Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends
Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Segment Trends

6. Global Antibody Drug Conjugates Market, By Application, 2020 - 2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Blood Cancer
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Breast Cancer
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Ovary Cancer
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Lung Cancer
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Skin Cancer
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Brain Tumor
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Others
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends

7. Global Antibody Drug Conjugates Market, By Distribution Channel , 2020 - 2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)

8. Global Antibody Drug Conjugates Market, By Region, 2020 - 2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2020 -2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2020 - 2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- AstraZeneca PLC
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Daiichi Sankyo Company, Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novasep
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ADC Therapeutics SA
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Alentis Therapeutics AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- F. Hoffmann-La Roche
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Gilead Sciences, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Biosion USA, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Astellas Pharma Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Duality Biologics (Suzhou) Co. Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- BioNTech SE
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- LaNova Medicines Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bliss Biopharmaceutical
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eisai Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ProfoundBio
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ImmunoGen Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mersana Therapeutics Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sorrento Therapeutics Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Oxford BioTherapeutics Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Takeda Pharmaceutical Company Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

抗体药物复合体市场按产品类型、连接子类型、应用、分销管道和地区划分

Antibody Drug Conjugates Market, By Product Type, By Linker Type, By Application, By Distribution Channel, By Geography

市场动态

目录

第一章：调查目标和前提条件

第二章市场展望

第三章：市场动态、监管与趋势分析

4. 2020-2032年全球抗体药物复合体市场（依产品类型划分）

5. 2020-2032年全球抗体药物复合体市场（依连接子类型划分）

6. 全球抗体药物复合体市场（按应用领域划分），2020-2032年

7. 2020-2032年全球抗体药物复合体市场（依通路划分）

8. 全球抗体药物复合体市场（按地区划分），2020-2032年

第九章竞争情势